Fig. 4

FMT recovers the protection of running in MI. A The schedule of FMT after ABX treated. B FMT from MI + Run increased EF and FS compared to FMT from MI + Control post-MI (n = 14:14). C FMT from MI + Run increased endurance capacity compared to FMT from MI + Control post-MI (n = 11:11). D, E FMT from MI + Run decreased cardiac ANP and BNP mRNA expression compared to FMT from MI + control post-MI (n = 6:6). F FMT from MI + Run decreased cardiac fibrosis compared to FMT from MI + control post-MI (n = 9:9). G FMT from MI + Run decreased cardiac cross sectional area compared to FMT from MI + control post-MI by H&E (n = 8:8). H FMT from MI + Run decreased cardiac cross sectional area compared to FMT from MI + control post-MI by WGA (n = 12:14). I FMT from MI + Run decreased Bax/Bcl₂, cleaved Caspase3/Caspase3 and collagen1 compared to FMT from MI + Control post-MI (n = 6:6). Scale bar: 50 μm in F and 25 μm in G and H. Data were represented as mean ± SD. Significant differences were assessed by two-tailed student t test. **p < 0.01, ***p < 0.001